Global CRO Pharmaceutical Product Development (PPD) has named David Simmons chairman and CEO. Simmons, an experienced pharmaceutical industry executive, joins PPD from Pfizer, where he was president and general manager of the emerging markets and established products business units. Simmons joins PPD June 4 and will be based at the company’s headquarters in Wilmington, N.C.

"David is a proven leader whose deep industry knowledge and vision will enable PPD to further its partnerships with pharmaceutical and biotech companies around the globe," said Stephen H. Wise, managing director of The Carlyle Group and PPD board member.

"This is a remarkable opportunity to join and lead a world-class pharmaceutical services organization through its next phase of prosperity and expansion,” said Simmons. “I look forward to working with PPD's seasoned leadership team and exceptional employees worldwide. Together, we will continue to grow the company and deliver quality results for clients and stakeholders."

Allen R. Thorpe, managing director of Hellman & Friedman and PPD board member, said, "David's wealth of pharmaceutical industry and international experience, combined with his well-honed leadership skills, will power PPD to meet the evolving needs of its clients. David is a client-focused leader with a keen understanding of the challenges and opportunities facing the biopharmaceutical industry."

Simmons joins PPD following 15 years with Pfizer in several senior roles. In his most recent position, he led units representing approximately $18.5 billion of Pfizer's annual revenue. His duties also included responsibility for the biosimilar development program. Prior to this role, Simmons held positions of increasing responsibility in information technology and pharmaceutical operations, including roles in several countries around the world.

PPD is owned by global alternative asset manager The Carlyle Group and private equity firm Hellman & Friedman, which jointly purchased PPD in December 2011.